Cellectis SA (NASDAQ:CLLS)’s share price was up 2.9% during mid-day trading on Monday . The company traded as high as $27.35 and last traded at $27.13, with a volume of 59,828 shares traded. The stock had previously closed at $26.37.

Several equities analysts have recently weighed in on CLLS shares. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Cellectis SA in a report on Sunday, May 8th. Zacks Investment Research lowered shares of Cellectis SA from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Cellectis SA in a report on Tuesday, May 31st. Finally, Ladenburg Thalmann started coverage on shares of Cellectis SA in a report on Tuesday, April 5th. They set a “buy” rating and a $45.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Cellectis SA currently has an average rating of “Buy” and a consensus price target of $43.60.

The company has a 50 day moving average of $26.44 and a 200 day moving average of $26.65. The company’s market capitalization is $954.68 million.

Cellectis SA (NASDAQ:CLLS) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.18. On average, equities research analysts expect that Cellectis SA will post ($1.72) earnings per share for the current year.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.